157 related articles for article (PubMed ID: 9085463)
1. Urinary transforming growth factor-beta 1 in relation to serum alpha-fetoprotein in hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Scand J Gastroenterol; 1997 Mar; 32(3):254-60. PubMed ID: 9085463
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; Yang ML; Ho MS; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Br J Cancer; 1997; 75(10):1460-6. PubMed ID: 9166938
[TBL] [Abstract][Full Text] [Related]
3. Urinary transforming growth factor α and serum α-fetoprotein as tumor markers of hepatocellular carcinoma.
Jeng JE; Tsai MF; Tsai HR; Chuang LY; Lin ZY; Hsieh MY; Chen SC; Chuang WL; Wang LY; Yu ML; Dai CY; Tsai JF
Tumour Biol; 2014 Apr; 35(4):3689-98. PubMed ID: 24375326
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of transforming growth factor-beta 1 in the urine of patients with hepatocellular carcinoma.
Tsai JF; Chuang LY; Jeng JE; Yang ML; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Medicine (Baltimore); 1997 May; 76(3):213-26. PubMed ID: 9193456
[TBL] [Abstract][Full Text] [Related]
5. Combined assessment of TGF-beta-1 and alpha-fetoprotein values improves specificity in the diagnosis of hepatocellular carcinoma and other chronic liver diseases in Malaysia.
Yasmin Anum MY; Looi ML; Nor Aini AH; Merican I; Wahidah A; Mohd Radzi AH; Nor Azizah A; Othman NH
Med J Malaysia; 2009 Sep; 64(3):223-7. PubMed ID: 20527273
[TBL] [Abstract][Full Text] [Related]
6. Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; Yang ML; Ho MS; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Br J Cancer; 1997; 76(2):244-50. PubMed ID: 9231926
[TBL] [Abstract][Full Text] [Related]
7. Serum insulin-like growth factor-II and alpha-fetoprotein as tumor markers of hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; You HL; Ho MS; Lai CS; Wang LY; Hsieh MY; Chen SC; Chuang WL; Lin ZY; Yu ML; Dai CY
Tumour Biol; 2003; 24(6):291-8. PubMed ID: 15004489
[TBL] [Abstract][Full Text] [Related]
8. TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma.
Mao L; Wang Y; Wang D; Han G; Fu S; Wang J
PLoS One; 2017; 12(9):e0183880. PubMed ID: 28902891
[TBL] [Abstract][Full Text] [Related]
9. Serological biomarkers of hepatocellular carcinoma in Egyptian patients.
El-Tayeh SF; Hussein TD; El-Houseini ME; Amer MA; El-Sherbini M; Elshemey WM
Dis Markers; 2012; 32(4):255-63. PubMed ID: 22430192
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of alpha-1-fetoprotein (AFP) as a biomarker for hepatocellular carcinoma recurrence after liver transplantation.
Nörthen A; Asendorf T; Walson PD; Oellerich M
Clin Biochem; 2018 Feb; 52():20-25. PubMed ID: 29054441
[TBL] [Abstract][Full Text] [Related]
11. Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma.
Vongsuvanh R; van der Poorten D; Iseli T; Strasser SI; McCaughan GW; George J
PLoS One; 2016; 11(5):e0155800. PubMed ID: 27219517
[TBL] [Abstract][Full Text] [Related]
12. Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis.
Wang Y; Yang H; Xu H; Lu X; Sang X; Zhong S; Huang J; Mao Y
J Gastroenterol Hepatol; 2014 Mar; 29(3):597-602. PubMed ID: 24236824
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated autoantibodies are useful biomarkers in immunodiagnosis of α-fetoprotein-negative hepatocellular carcinoma.
Wang T; Liu M; Zheng SJ; Bian DD; Zhang JY; Yao J; Zheng QF; Shi AM; Li WH; Li L; Chen Y; Wang JH; Duan ZP; Dong L
World J Gastroenterol; 2017 May; 23(19):3496-3504. PubMed ID: 28596685
[TBL] [Abstract][Full Text] [Related]
14. Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis.
Chang TS; Wu YC; Tung SY; Wei KL; Hsieh YY; Huang HC; Chen WM; Shen CH; Lu CH; Wu CS; Tsai YH; Huang YH
Am J Gastroenterol; 2015 Jun; 110(6):836-44; quiz 845. PubMed ID: 25869392
[TBL] [Abstract][Full Text] [Related]
15. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis.
Zhang J; Chen G; Zhang P; Zhang J; Li X; Gan D; Cao X; Han M; Du H; Ye Y
PLoS One; 2020; 15(2):e0228857. PubMed ID: 32053643
[TBL] [Abstract][Full Text] [Related]
16. Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
Zekri AR; Youssef AS; Bakr YM; Gabr RM; Ahmed OS; Elberry MH; Mayla AM; Abouelhoda M; Bahnassy AA
World J Gastroenterol; 2016 Apr; 22(16):4168-82. PubMed ID: 27122667
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma.
Ilikhan SU; Bilici M; Sahin H; Akca AS; Can M; Oz II; Guven B; Buyukuysal MC; Ustundag Y
World J Gastroenterol; 2015 Jun; 21(22):6999-7007. PubMed ID: 26078578
[TBL] [Abstract][Full Text] [Related]
18. Combination of DKK1 and AFP improves diagnostic accuracy of hepatocellular carcinoma compared with either marker alone.
Erdal H; Gül Utku Ö; Karatay E; Çelik B; Elbeg Ş; Doğan İ
Turk J Gastroenterol; 2016 Jul; 27(4):375-81. PubMed ID: 27458854
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of α-fetoprotein as a diagnostic tool for hepatocellular carcinoma in Korea.
Ahn DG; Kim HJ; Kang H; Lee HW; Bae SH; Lee JH; Paik YH; Lee JS
Korean J Intern Med; 2016 Jan; 31(1):46-53. PubMed ID: 26767857
[TBL] [Abstract][Full Text] [Related]
20. Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers.
Ricco G; Cavallone D; Cosma C; Caviglia GP; Oliveri F; Biasiolo A; Abate ML; Plebani M; Smedile A; Bonino F; Pontisso P; Brunetto MR
Cancer Biomark; 2018 Feb; 21(3):603-612. PubMed ID: 29278878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
